Bicara Therapeutics Inc.
BCAX
$26.87
$0.532.01%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 56.43% | 62.54% | 92.40% | 102.00% | 111.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.98% | 88.87% | 103.23% | 107.52% | 131.86% |
| Operating Income | -59.98% | -88.87% | -103.23% | -107.52% | -131.86% |
| Income Before Tax | -70.64% | -103.12% | -103.74% | -57.88% | -64.02% |
| Income Tax Expenses | -23.64% | 16.04% | 5,733.33% | 5,066.67% | 4,200.00% |
| Earnings from Continuing Operations | -70.38% | -102.88% | -104.31% | -58.34% | -64.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.38% | -102.88% | -104.31% | -58.34% | -64.46% |
| EBIT | -59.98% | -88.87% | -103.23% | -107.52% | -131.86% |
| EBITDA | -59.95% | -88.87% | -103.28% | -107.56% | -131.87% |
| EPS Basic | 87.21% | 93.68% | 96.24% | 96.70% | 76.49% |
| Normalized Basic EPS | 87.23% | 93.69% | 96.25% | 96.70% | 76.49% |
| EPS Diluted | 87.21% | 93.68% | 96.24% | 96.70% | 76.49% |
| Normalized Diluted EPS | 87.23% | 93.69% | 96.25% | 96.70% | 76.49% |
| Average Basic Shares Outstanding | 86.41% | 226.99% | 1,565.51% | 6,160.20% | 4,857.84% |
| Average Diluted Shares Outstanding | 86.41% | 226.99% | 1,565.51% | 6,160.20% | 4,857.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |